In the BioHarmony Drug Report Database

"Preview" Icon

Paclitaxel

Abraxane, Taxol, Apealea (paclitaxel) is a small molecule pharmaceutical. Paclitaxel was first approved as Abraxane on 1992-12-29. It is used to treat breast neoplasms, kaposi sarcoma, non-small-cell lung carcinoma, and ovarian neoplasms in the USA. It has been approved in Europe to treat breast neoplasms, non-small-cell lung carcinoma, ovarian neoplasms, and pancreatic neoplasms. The pharmaceutical is active against tubulin beta chain. In addition, it is known to target toll-like receptor 4 and nuclear receptor subfamily 1 group I member 2. Paclitaxel’s patents are valid until 2034-01-12 (FDA).

 

Trade Name

 

Abraxane, Apealea
 

Common Name

 

paclitaxel
 

ChEMBL ID

 

CHEMBL428647
 

Indication

 

breast neoplasms, kaposi sarcoma, non-small-cell lung carcinoma, ovarian neoplasms, pancreatic neoplasms
 

Drug Class

 

Antineoplastics, taxane derivatives

Image (chem structure or protein)

Paclitaxel structure rendering